Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Aspirin in Pain: NCT07281547 Clinical Landscape Report 2026
18 September 2026
NCT07281547 clinical landscape for Pain: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mocertatug Rezetecan in Endometrial Carcinoma: NCT07286331 Clinical Landscape Report 2026
18 September 2026
NCT07286331 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ruxolitinib Phosphate in Peripheral T-Cell Lymphoma: NCT07283822 Clinical Landscape Report 2026
18 September 2026
NCT07283822 clinical landscape for Peripheral T-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Metastatic Soft Tissue Sarcoma: NCT07283731 Clinical Landscape Report 2026
18 September 2026
NCT07283731 clinical landscape for Metastatic Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
AVC-203 in Relapsing acute myeloid leukemia: NCT07284433 Clinical Landscape Report 2026
18 September 2026
NCT07284433 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Serplulimab in Triple Negative Breast Cancer: NCT07283692 Clinical Landscape Report 2026
18 September 2026
NCT07283692 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lifileucel in Melanoma, Cutaneous Malignant: NCT07288203 Clinical Landscape Report 2026
18 September 2026
NCT07288203 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dubodencel in Refractory Melanoma: NCT07288112 Clinical Landscape Report 2026
18 September 2026
NCT07288112 clinical landscape for Refractory Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fulvestrant in HR-positive/HER2-low Breast Carcinoma: NCT07287917 Clinical Landscape Report 2026
18 September 2026
NCT07287917 clinical landscape for HR-positive/HER2-low Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Methylprednisolone in Amyotrophic Lateral Sclerosis: NCT07287397 Clinical Landscape Report 2026
18 September 2026
NCT07287397 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Metformin Hydrochloride in Metastatic Soft Tissue Sarcoma: NCT07291297 Clinical Landscape Report 2026
18 September 2026
NCT07291297 clinical landscape for Metastatic Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Triple Negative Breast Cancer: NCT07297667 Clinical Landscape Report 2026
18 September 2026
NCT07297667 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.